Twitter Beğeni Hilesi

Celebrating the Jewish New Year with the Urology Department at TASMC. Great opportunity to thank the staff for all the help and support. Looking forward to the years to come.

Preliminary data for this year’s residency application cycle are now available. These figures won’t surprise anyone familiar with the contemporary application process… but if you’ve been out of the game for a while, some of the numbers will be eye-popping. #ApplicationFever

Interested in learning more about the oldest and largest Society of Urologic Oncology fellowship? Come join us at our virtual open house Wednesday Nov 16th 7 pm EST. docs.google.com/forms/d/e/1FAI… (zoom link to follow)

Come check us out. Incredible breadth of research opportunities and unmatched clinical volume.

The best way to see Van Gogh's "Starry Night" is to stare at the center of the spiral for 20 seconds and then look at the painting

Maria was a very kind, compassionate, brilliant and beautiful soul who lit up the room and enriched the lives of all of those she met. She will be profoundly missed but certainly never forgotten. 😔💔

Tandem ureteral stents are commonly used to drain malignant ureteral obstruction. With the following article we tried to identify those patients who will benefit the most from this type of drainage. Taylor & Francis Research Insights Roy Mano Ziv Savin Mario Sofer Yuval Bar-Yosef tandfonline.com/doi/full/10.10…

Now published in Journal of Geriatric Oncology a collaboration by TLVMC Department of Urology Ziv Savin Roy Mano Shay Golan IUOC et al. 11-item modified frailty index and outcomes after radical cystectomy. geriatriconcology.net/article/S1879-…

Performance of standard systematic biopsy versus MRI/TRUS fusion biopsy using the Navigo® system in contemporary cohort buff.ly/3IjYDrp

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Now published in Journal of Urology by UrologyMSK Vincent Laudone John P. Mulhall MD et al.: Do phosphodiesterase type 5 inhibitors increase the risk of biochemical recurrence after radical prostatectomy? auajournals.org/doi/10.1097/JU…

Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer buff.ly/3UrXJAk

Are some of these patients candidates for RARC+UCS? Haim Herzberg and Roy Mano just published their excellent work in UO about the natural history of non-curative treatment for MIBC. Reporting 65% of the patients suffered from recurrent hematuria and 37% carried a nephrostomy